Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.49 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
| ▸ | LYN | P07948 | 1/20 | 0.35 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.35 |
| ▸ | MAP3K8 | P41279 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL937872 | 0.88 | EGFR (0.62) | EGFRERBB2 | |
| SCHEMBL938691 | 0.85 | ERBB2 (0.51) | EGFRERBB2KCNH2ERBB4 | |
| SCHEMBL938568 | 0.84 | EGFR (0.60) | EGFRERBB2KCNH2ERBB4PRKCQ | |
| SCHEMBL12908993 | 0.80 | EGFR (0.57) | EGFRERBB2 | |
| SCHEMBL938318 | 0.79 | STK3 (0.52) | EGFRERBB2KCNH2ERBB4LYN | |
| SCHEMBL12909158 | 0.76 | EGFR (0.82) | EGFRERBB2KCNH2 | |
| SCHEMBL13372627 | 0.76 | EGFR (0.82) | EGFRERBB2KCNH2 | |
| SCHEMBL937835 | 0.75 | EGFR (0.50) | EGFRPRKCQMAP3K8 | |
| SCHEMBL12944770 | 0.75 | SIGMAR1 (0.42) | EGFRERBB2PRKCQ | |
| SCHEMBL939013 | 0.73 | EGFR (0.76) | EGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524722-B2 | Substituted tricyclic compounds and methods of use thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2212332-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER IP GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2009033581-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021493-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | CYP11B2, CYP11B1, CYP11A1 | EGFR 1771/4885ERBB2 1732/4885KCNH2 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.